Previous Close | 8.00 |
Open | 7.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 30.00 |
Expire Date | 2024-12-20 |
Day's Range | 7.00 - 8.00 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
This biotech stock nears a buy point after an explosive move following positive drug trial news. Sales have grown by triple-digits for seven quarters.
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.